查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
家族性高膽固醇血症治療的全球市場(2022年～2029年)
市場調查報告書
商品編碼
1078231

家族性高膽固醇血症治療的全球市場(2022年～2029年)

Global Familial Hypercholesterolemia Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 185 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球家族性高膽固醇血症治療市場調查，提供市場概要，市場規模和預測，趨勢，成長要素及課題，客戶形勢，藥物類型·適應症類型·流通管道·各地區的分析，新企業簡介等資訊。

目錄

第1章 家族性高膽固醇血症治療市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 家族性高膽固醇血症治療藥市場:市場定義和概要

第3章 家族性高膽固醇血症治療藥市場:摘要整理

  • 藥物各類型的市場明細
  • 各適應症類型的市場明細
  • 流通管道市場內譯
  • 各地區的市場明細

第4章 家族性高膽固醇血症治療市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 家族性高膽固醇血症治療市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 未滿足需求

第6章 家族性高膽固醇血症治療市場:COVID-19分析

  • 市場的COVID-19影響分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後或未來方案
  • COVID-19的價格變動
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 家族性高膽固醇血症治療藥市場:藥物各類型

  • 簡介
  • 藥物各類型的市場規模分析，及與前一年同期比較成長分析
  • 藥物各類型的市場魅力指數
    • Statin他汀類藥物
    • 聯合膽固醇吸收抑製劑和他汀類藥物
    • 依折麥布（Zetia）
    • PCSK9 抑製劑
    • 貝特類
    • Omega-3 脂肪酸補充劑
    • 其他

第8章 家族性高膽固醇血症治療藥市場:各適應症類型

  • 簡介
  • 各適應症類型的市場規模分析，及與前一年同期比較成長分析
  • 各適應症類型的市場魅力指數
    • hetero連接型家族性高膽固醇血症
    • 均質連接型家族性高膽固醇血症

第9章 家族性高膽固醇血症治療藥市場:各流通管道

  • 簡介
    • 各流通管道的市場規模分析，及與前一年同期比較成長分析
    • 各流通管道的市場魅力指數
  • 醫院藥局
    • 簡介
    • 市場規模分析(2020年～2029年，及2021年～2029年)
  • 零售藥局
  • 其他

第10章 家族性高膽固醇血症治療藥市場:各地區

  • 簡介
    • 各地區的市場規模分析(2020年～2029年，及2021年～2029年)
    • 各地區的市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 藥物各類型的市場規模分析，及與前一年同期比較成長分析
    • 各適應症類型的市場規模分析，及與前一年同期比較成長分析
    • 各流通管道的市場規模分析，及與前一年同期比較成長分析
    • 各國市場規模分析，及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 藥物各類型的市場規模分析，及與前一年同期比較成長分析
    • 各適應症類型的市場規模分析，及與前一年同期比較成長分析
    • 各流通管道的市場規模分析，及與前一年同期比較成長分析
    • 各國市場規模分析，及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要地區具體動態
    • 藥物各類型的市場規模分析，及與前一年同期比較成長分析
    • 各適應症類型的市場規模分析，及與前一年同期比較成長分析
    • 各流通管道的市場規模分析，及與前一年同期比較成長分析
    • 各國市場規模分析，及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 藥物各類型的市場規模分析，及與前一年同期比較成長分析
    • 各適應症類型的市場規模分析，及與前一年同期比較成長分析
    • 各流通管道的市場規模分析，及與前一年同期比較成長分析
    • 各國市場規模分析，及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 藥物各類型的市場規模分析，及與前一年同期比較成長分析
    • 各適應症類型的市場規模分析，及與前一年同期比較成長分析
    • 各流通管道的市場規模分析，及與前一年同期比較成長分析

第11章 家族性高膽固醇血症治療市場:競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第12章 家族性高膽固醇血症治療市場:企業簡介概要

  • Novartis AG
    • 企業概要
    • 產品系列·種類
    • 主要亮點
    • 財務概要
  • Amryt Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Regeneron Pharmaceuticals
  • Amgen Inc
  • Daiichi Sankyo Company Limited
  • Esperion Therapeutics
  • Viatris Inc.
  • Kowa Pharmaceuticals America, Inc.
  • Merck & Co., Inc.

第13章 家族性高膽固醇血症治療藥市場:DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
簡介目錄
Product Code: DMPH5154

Market Overview

The global familial hypercholesterolemia treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Familial hypercholesterolemia is a genetic disease that runs in families. It raises LDL (bad) cholesterol levels dramatically. The disease starts at birth and can lead to heart attacks at a young age.

Market Dynamics

The factors influencing the familial hypercholesterolemia treatment market are the increasing FDA approvals and demand for familial hypercholesterolemia treatment and the growing prevalence of familial hypercholesterolemia.

The increasing FDA approvals and demand for familial hypercholesterolemia treatment are expected to drive the market growth

Familial hypercholesterolemia is a genetic disease that runs in families. It raises LDL (bad) cholesterol levels dramatically. The disease starts at birth and can lead to heart attacks at a young age. LDL cholesterol levels of over 190 mg/dL in adults (and over 160 mg/dL in children) are among the most common signs of FH. Furthermore, most FH people have a family history of early heart disease or heart attacks. Routine blood cholesterol screening can reveal elevated LDL levels in some cases.

The use of novel therapies as an adjunctive treatment for HoFH has been approved. Lomitapide, a microsomal triglyceride transfer protein inhibitor, can lower LDL-C by up to 46 percent in people over 18. In addition, injectable mipomersen, an antisense RNA therapy, is approved in the United States for children as young as 12 years old and can lower LDL-C by up to 25%. Monoclonal antibodies to PCSK9 are being touted as a new treatment option for FH. Moreover, the increasing FDA approvals are expected to drive market growth. For instance, on April 1st, 2021, Praluent (alirocumab) injection was approved by the Food and Drug Administration (FDA) for adult patients with homozygous familial hypercholesterolemia (HoFH). This genetic condition causes severely high cholesterol. Praluent isn't meant to be used on its own; it's meant to be combined with other HoFH treatments.

Limitations associated with familial hypercholesterolemia disease are expected to hamper the market growth

FH is frequently misdiagnosed and mistreated, especially in children. 10 Primary care providers bear the burden of early FH diagnosis. They have a unique opportunity to improve FH detection and management. 11 The National Heart, Lung, and Blood Institute, American Academy of Pediatrics, American Heart Association, National Lipid Association, and American College of Cardiology all recommend universal lipid screening in children aged 9 to 11 years, which has the potential to significantly improve case finding. Moreover, there are currently no long-term studies in children with FH that show a reduction in vascular events when LDL-C lowering treatment is started early. According to the study, children with FH have significantly greater carotid intimamedia thickness than their unaffected siblings, which can be detected as early as 8 to 10 years old.

COVID-19 Impact Analysis

Patients with familial hypercholesterolemia (FH) are more likely to develop COVID-19 complications during the infection's acute phase and for a long time afterward. Because the level of low-density lipoprotein cholesterol (LDL-C) in FH patients is elevated from birth and correlates with the degree of systemic endothelial dysfunction, both heterozygous FH (HeFH) and, in particular, homozygous FH (HoFH) patients have a dysfunctional endothelium that is vulnerable to further damage from the direct viral attack and the hyper-inflammatory response typical of severe COVID-19. The use of statins in patients with COVID-19 has been beneficial in the past. Therefore, the focus on FH patients should be on lowering LDL-C levels effectively, as this is the root cause of the expected increased vulnerability to COVID-19 infection. During the COVID pandemic, continued use of statins and other lipid-lowering therapies should be encouraged to reduce the risk of COVID-19-related cardiovascular complications. Hence, the covid-19 is expected to positively impact the market growth.

Segment Analysis

Based on drugs, the statins segment is expected to drive the market growth in the forecast period

Statins are microorganism-derived drugs that significantly reduce cholesterol synthesis in cells by inhibiting the enzyme HMG-CoA reductase's activity. Statins, on the other hand, lower cholesterol levels in the blood by increasing the number of high-affinity receptors that recognize plasma LDL and decreasing the rate of VLDL synthesis in the liver. This explains why these drugs have a minor triglyceride-lowering effect. The efficacy of statins in lowering plasma cholesterol levels is comparable to that of bile acid-binding polymers, but it is superior to that of fibrates and nicotinic acid. Statins have a better tolerability profile than the other two drugs, but they are less effective at lowering plasma triglycerides and increasing HDL cholesterol levels. At their maximum approved doses, the strongest statins, rosuvastatin, and atorvastatin, can reduce LDLc levels by 50-60%. Moreover, the FDA approvals of this drug are expected to boost its market growth. For instance, on 22nd December 2021, the FDA approved Leqvio (inclisiran) injection for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein lowering in addition to diet and maximally tolerated statin therapy.

Geographical Analysis

North America region is expected to hold the largest market share in the global familial hypercholesterolemia treatment market

The growing prevalence of familial hypercholesterolemia and increasing FDA approvals in this region is expected to drive the market growth.

The prevalence of probable/definite FH in the United States was estimated at 0.40 percent (95 percent confidence interval [CI], 0.32-0.48), or 1 in 250 people (95 percent CI, 1 in 311 to 209). This means that 834,500 adults in the United States have FH. According to studies, the prevalence of heterozygous FH in the general population in the United States and worldwide is 1 in 250.

Moreover, on 23rd December 2021, The US Food and Drug Administration (FDA) approved Inclisiran (Leqvio) for lowering LDL-C in patients with atherosclerotic cardiovascular disease or heterozygous hypercholesterolemia.

Competitive Landscape

The global Familial Hypercholesterolemia Treatment Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Amryt Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc., Regeneron Pharmaceuticals, Sanofi S.A., Amgen Inc., Daiichi Sankyo Company Limited, Esperion Therapeutics, Viatris Inc., Kowa Pharmaceuticals America, Inc. and Merck & Co., Inc.

Novartis AG

Overview: Novartis International AG, based in Basel, Switzerland, is a multinational pharmaceutical corporation. It is one of the world's largest pharmaceutical corporations. The company was founded in 1996.

Product Portfolio: LEQVIO (inclisiran) is an injectable prescription medicine used in adults who need additional lowering of "bad" cholesterol (LDL-C) and have heterozygous familial hypercholesterolemia (HeFH).

Key Development: On 23rd December 2021, The US Food and Drug Administration (FDA) approved Novarti's Inclisiran (Leqvio) to lower LDL-C in patients with atherosclerotic cardiovascular disease heterozygous hypercholesterolemia.

Why Purchase the Report?

Visualize the composition of the global familial hypercholesterolemia treatment market segmentation by drug type, indication type, and distribution channel, highlighting the key commercial assets and players.

identify commercial opportunities in global familial hypercholesterolemia treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global familial hypercholesterolemia treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global familial hypercholesterolemia treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Familial Hypercholesterolemia Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Familial Hypercholesterolemia Treatment Market- Market Definition and Overview

3. Familial Hypercholesterolemia Treatment Market- Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market Snippet By Indication Type
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet By Region

4. Familial Hypercholesterolemia Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing FDA approvals and demand for familial hypercholesterolemia treatment
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with familial hypercholesterolemia disease
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Familial Hypercholesterolemia Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Familial Hypercholesterolemia Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Familial Hypercholesterolemia Treatment Market- By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.3. Market Attractiveness Index, By Drug Type
    • 7.3.1. Statins
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.3.1.1.3. Atorvastatin (Lipitor)
      • 7.3.1.1.4. Fluvastatin (Lescol XL)
      • 7.3.1.1.5. Lovastatin (Altoprev)
      • 7.3.1.1.6. Pitavastatin (Livalo, Zypitamag)
      • 7.3.1.1.7. Pravastatin (Pravachol)
      • 7.3.1.1.8. Rosuvastatin (Crestor, Ezallor)
      • 7.3.1.1.9. Simvastatin (Zocor)
    • 7.3.2. Combination cholesterol absorption inhibitor and statin
    • 7.3.3. Ezetimibe (Zetia)
    • 7.3.4. PCSK9 inhibitors
    • 7.3.5. Fibrates
    • 7.3.6. Omega-3 fatty acid supplements
    • 7.3.7. Others

8. Familial Hypercholesterolemia Treatment Market-By Indication Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
  • 8.3. Market Attractiveness Index, By Indication Type
    • 8.3.1. Heterozygous familial hypercholesterolemia
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3.2. Homozygous familial hypercholesterolemia

9. Familial Hypercholesterolemia Treatment Market- By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Other

10. Familial Hypercholesterolemia Treatment Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Familial Hypercholesterolemia Treatment Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Familial Hypercholesterolemia Treatment Market- Company Profiles

  • 12.1. Novartis AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Amryt Pharmaceuticals, Inc.
  • 12.3. AstraZeneca Plc
  • 12.4. Regeneron Pharmaceuticals
  • 12.5. Amgen Inc
  • 12.6. Daiichi Sankyo Company Limited
  • 12.7. Esperion Therapeutics
  • 12.8. Viatris Inc.
  • 12.9. Kowa Pharmaceuticals America, Inc.
  • 12.10. Merck & Co., Inc.

LIST NOT EXHAUSTIVE

13. Familial Hypercholesterolemia Treatment Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us